Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Autoimmune Pulmonary Alveolar Proteinosis
NCT03231033Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Aug 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pioglitazone in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Occurrence of any treatment-emergent adverse events and serious adverse events at 1 year. Started Aug 2017; status: completed.
02
Drugs
pioglitazone
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT03231033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231033.